Results 111 to 120 of about 67,152 (253)

Direct Oral Anticoagulants for Acute Venous Thromboembolism [PDF]

, 2013
Peter Verhamme, Henri Bounameaux
openalex   +1 more source

Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials [PDF]

, 2014
Nick van Es, Michiel Coppens, Sam Schulman, Saskia Middeldorp, Harry R. Büller   +4 more
openalex   +1 more source

Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism [PDF]

, 2014
Ho‐Young Yhim, Soo‐Mee Bang
openalex   +1 more source

Real clinical practice data: comparison of the efficacy and safety of apixaban and rivaroxaban in the treatment of VTE

Евразийский Кардиологический Журнал, 2022
Venous thromboembolic complications (VTEC), including deep vein thrombosis (DVT) and pulmonary embolism (PE), are common pathologies of the cardiovascular system.
article Editorial
doaj  

Direct Oral Anticoagulants for Pulmonary Embolism

Hämostaseologie
AbstractVenous thromboembolism (VTE) is the third most common cardiovascular disease. For most patients, the standard of treatment has long consisted on low-molecular-weight heparin followed by vitamin K antagonists, but a number of clinical trials and, subsequently, post-marketing studies have shown that direct oral anticoagulants (DOACs) with or ...
Pizzi R., Cimini L. A., Ageno W., Becattini C.   +3 more
openaire   +2 more sources

Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review

Рациональная фармакотерапия в кардиологии, 2019
Direct oral anticoagulants (not vitamin K antagonists), unlike standard oral anticoagulants (e.g. warfarin), have a predictable manifestation of the anticoagulant effect and the possibility of using a fixed dose without the need for constant monitoring ...
B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov   +2 more
doaj   +2 more sources

Antithrombotic Treatment and Clinical Outcomes After Intracerebral Hemorrhage: A Retrospective Cohort Study from the Swedish Stroke Register

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background A rapid shift has occurred from vitamin K antagonists toward direct oral anticoagulants, which have a lower risk of intracerebral hemorrhage (ICH). However, effects on clinical outcomes after ICH are understudied.
Mattias Tallroth, Ruzan Udumyan, András Büki, Mia von Euler   +3 more
doaj   +1 more source

Use of direct oral anticoagulants in thromboembolic disease [PDF]

, 2016
Matthew R. Wilson, Kieran F. Docherty, Roy S. Gardner   +2 more
openalex   +1 more source

Risk of Direct Oral Anticoagulant Bioaccumulation in Patients with Pulmonary Hypertension [PDF]

, 2016
Laurence Gabriël, Xavier Delavenne, Pierrick Bedouch, C. Khouatra, Hélène Bouvaist, Jean-François Cordier, Jean‐François Mornex, Christophe Pison, Vincent Cottin, Laurent Bertoletti   +9 more
openalex   +1 more source

Efficacy and Safety of Direct Oral Anticoagulants Compared to Warfarin in Prevention of Thromboembolic Events Among Elderly Patients with Atrial Fibrillation [PDF]

, 2016
Shilpa D. Kailas, Sirisha Reddy Thambuluru   +1 more
openalex   +1 more source